1+ hour, 9+ min ago   (441+ words) Every few years, drug development goes through a moment where a new technology promises to change everything. Artificial intelligence is having that moment now. Unlike some previous waves of hype, this one is grounded in something real, but only if…...

23+ hour, 39+ min ago   (809+ words) Drug development is an inherently risky endeavour, with the average probability of approval for a drug entering Phase I studies now sitting at just 6.7%. While much of this can be attributed to lack of efficacy, factors such as poor clinical…...

2+ mon, 3+ week ago   (615+ words) AI company Anthropic has launched a new large language model (LLM) – Claude Fable 5 – claiming its capabilities as a tool for drug discovery and scientific research gives it a big lead over other platforms. The autonomous AI is the first to be…...

4+ mon, 3+ day ago   (507+ words) Dr Natalie Kaempf and Prof Patrik Verstreken. Researchers have used a machine learning algorithm to try to work out why Parkinson's disease patients can respond so differently to treatment, and guide the development of personalised medicines. The team, led by…...

4+ mon, 3+ week ago   (842+ words) InsightBrain gives commercial leaders the signals and direction to deliver stronger launches, defend share, and stay ahead of the competition. InsightBrain can be deployed for a single high-stakes project or embedded as an evolving capability that grows with the organisation....

6+ mon, 2+ week ago   (514+ words) MSD has signed a deal with the Mayo Clinic that will allow it to use the health system's genomic and clinical data for drug discovery. The two will apply AI and advanced analytics to the project, which they say marks…...

7+ mon, 5+ day ago   (542+ words) There’s no doubt that large language models and generative AI tools have taken the world by storm. Their ability to create, automate, and analyse is continuing to transform the way we work and interact as never before, but the real…...

7+ mon, 5+ day ago   (131+ words) Outdated training and behaviours impact patient outcomes and can lead to patient risk. In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Lisa Sims, executive director of learning strategy & operations at Novartis, for a conversation on modern training…...

7+ mon, 1+ week ago   (354+ words) As the "zero-click" era, fuelled by generative AI, reshapes how intent is formed and information is consumed, the critical need for a new analytical paradigm is not just emerging – it is here. Welcome to the era where the convergence of…...

7+ mon, 1+ week ago   (674+ words) Finding treatments for diseases afflicting humanity often proceeds at a crawl, leaving many serious medical needs unmet. Solving this problem requires a fundamentally novel approach to finding drugs. Adityo Prakash, CEO of drug discovery platform Verseon, spoke with pharmaphorum to…...